Eli Lilly (LLY)
(Delayed Data from NYSE)
$733.51 USD
+8.64 (1.19%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $733.20 -0.31 (-0.04%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth A Momentum D VGM
Price, Consensus and EPS Surprise
LLY 733.51 +8.64(1.19%)
Will LLY be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for LLY based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for LLY
Gear Up for Lilly (LLY) Q1 Earnings: Wall Street Estimates for Key Metrics
Zacks Industry Outlook Highlights Eli Lilly, Novo Nordisk, Merck and AbbVie
LLY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Will Healthcare ETFs Lose Momentum as Q1 Earnings Unfold?
4 Large Drug Stocks to Hold on to Amid Industry Challenges
Analysts Estimate Pfizer (PFE) to Report a Decline in Earnings: What to Look Out for
Other News for LLY
IN BRIEF: Eli Lilly urges shareholders to reject Tutanota's offer
SPDR ETF Report For Friday, April 26
ClearBridge Global Growth Strategy Q1 2024 Portfolio Manager Commentary
Novo Nordisk: Medicare Coverage To Unlock Another Big Market For Wegovy
AstraZeneca: Strong In A Weak Market